Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2008-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the highest, tolerated dose level and safety of
lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the
clinical activity of the combination of drugs in subjects with previously untreated advanced
or metastatic colorectal cancer.